We applied this approach to study the systemic effects of sodium-glucose linked transporter-2 (SGLT-2) inhibition on subsequently isolated synaptosomal glucose metabolism in the 5X-FAD mouse model of Alzheimer’s Disease. The gene discussed is SLC5A2; the disease is early-onset autosomal dominant Alzheimer disease.